The International Conference on Harmonization (ICH) focuses on fostering harmonization in the interpretation and application of technical guidelines for pharmaceutical product registration. Established in 1990, the ICH unites regulatory authorities and pharmaceutical industry associations from Europe, Japan, and the United States. This collaboration aims to streamline the regulatory assessment process for new drug applications, reduce development times, and optimize resources for drug development, ultimately benefitting public health.
ICH’s Quality guidelines, including ICH Q8 Pharmaceutical Development, ICH Q9 Quality Risk Management, and ICH Q10 Pharmaceutical Quality System, were developed to address challenges in the pharmaceutical industry stemming from technological advancements and new opportunities in drug development and manufacturing. These guidelines introduced a quality vision centered on science- and risk-based concepts, emphasizing an integrated quality system.
To ensure consistent implementation of ICH Q8, Q9, and Q10, the Quality Implementation Working group (Q–IWG) was established. This group aimed to maximize the benefits derived from the interaction between these guidelines. Moreover, the development of ICH Q11 was supported to maintain a harmonized approach within the industry.
The Q–IWG created a Question-and-Answer document (Q&A) to address key inquiries related to the guidelines, covering topics such as process validation, quality by design (QbD), and the pharmaceutical quality system. Additionally, training workshops were conducted globally to illustrate how a science- and risk-based approach to product development could impact regulatory assessment and post-approval manufacturing.
Further clarifications were provided through “Points-to-Consider” documents, supplementing the existing Q&A document and workshop materials. These documents covered critical areas such as establishing critical quality attributes (CQAs) and critical process parameters (CPPs), developing control strategies, and defining the level of documentation necessary for regulatory submissions.
The Points-to-Consider document emphasized the importance of control strategy over the product lifecycle, continual improvement, and change management. It provided insights into the suitability of control strategy at different scales, specifications for real-time release testing (RTRT), and decision-making processes for batch release. Additionally, guidance on the role of modeling in Quality by Design (QbD) and process validation was highlighted to enhance industry practices.
Since its inception in 2003, ICH has focused on providing guidance and training materials for the global implementation of science- and risk-based approaches in drug development and manufacturing. By integrating these principles, quality is embedded in pharmaceutical products, leading to reduced complaints, deviations, recalls, and inspection observations, ultimately benefiting patients worldwide.
The comprehensive efforts of the ICH Quality Implementation Working Group, with members spanning key industry experts, have been instrumental in driving the harmonization and effective implementation of ICH guidelines. Their dedication to enhancing regulatory practices and industry standards underscores the commitment to advancing pharmaceutical quality and safety.
Takeaways:
– The implementation support for ICH Q8, Q9, and Q10 plays a crucial role in harmonizing pharmaceutical quality practices globally.
– Clarifications provided through Q&A documents and training workshops enhance understanding and application of science- and risk-based approaches.
– Points-to-Consider documents offer detailed insights into critical quality attributes, control strategies, and regulatory submission requirements, promoting best practices in the industry.
Tags: regulatory, formulation
Read more on pharmtech.com